A drug that can prolong the lives of patients with advanced liver cancer has been rejected for use in the NHS in England, Wales and Northern Ireland.

The National Institute for Health and Clinical Excellence (NICE) said the cost of Nexavar – about £3,000 a month – was “simply too high”. BBC.

I’d not like to have to make these sorts of decisions – at the end of the day the Health Service resources aren’t limitless and £3,000 a month is a lot it – although it wouldn’t seem quite so much if your life depended on it.

What no-one seems to be asking is how Bayer justify such an exorbitant price – what was their development costs, what’s the production costs and what’s the payback period – questions that we’ll never get straight answers to – all you can say is Bayer made €1,719 million last year – plenty of profit margin.

The whole sorry tale confirms what we all know – health care is for the rich.